Hancock Jaffe Laboratories, Inc. (HJLI): Price and Financial Metrics
HJLI Price/Volume Stats
| Current price | $10.38 | 52-week high | $17.68 |
| Prev. close | $10.59 | 52-week low | $4.99 |
| Day low | $10.26 | Volume | 221,800 |
| Day high | $10.75 | Avg. volume | 522,396 |
| 50-day MA | $7.75 | Dividend yield | N/A |
| 200-day MA | $7.25 | Market Cap | 90.15M |
HJLI Stock Price Chart Interactive Chart >
Hancock Jaffe Laboratories, Inc. (HJLI) Company Bio
Hancock Jaffe Laboratories, Inc., a development stage medical device company, develops and sells biological tissue solutions to treat patients with coronary, vascular, end stage renal, and peripheral arterial diseases in the United States and Europe. The company develops and manufactures implantable cardiovascular bioprosthetic devices for patients with cardiovascular disease, peripheral arterial and venous disease, and end stage renal disease. Its products include the Bioprosthetic Heart Valve, a bio-prosthetic heart valve designed to mimic and function like a native heart valve; the CoreoGraft, a device for use as an alternate or supplemental coronary vascular conduit in coronary bypass surgery; and the Venous Valve, a bioprosthetic, pig venous valve for patients with lower limb chronic venous insufficiency. The company was founded in 1987 and is based in Irvine, California. As of July 18, 2006, Hancock Jaffe Laboratories, Inc. is a subsidiary of Leman Cardiovascular SA.
Latest HJLI News From Around the Web
Below are the latest news stories about Hancock Jaffe Laboratories Inc that investors may wish to consider to help them evaluate HJLI as an investment opportunity.
enVVeno Medical Corporation Successfully Completes RebrandingCompany Now Trading Under Ticker Symbol "NVNO"IRVINE, CA / ACCESSWIRE / October 1, 2021 / enVVeno Medical Corporation (NASDAQ:NVNO) ("enVVeno" or the "Company"), a company setting new standards of care for the treatment of venous disease, announced today that it has successfully completed its rebranding and that its shares are now trading under the ticker symbol "NVNO" on The Nasdaq Capital Market. The Company was formerly called Hancock Jaffe Laboratories, Inc. |
Hancock Jaffe to Participate in the Duologue Series Virtual Webinar Hosted by Ladenburg ThalmannLive webinar followed by Q&A on Monday, September 27th at 1:00 PM ET with Robert Berman Chief Executive Officer of Hancock Jaffe LaboratoriesIRVINE, CA / ACCESSWIRE / September 24, 2021 / Hancock Jaffe Laboratories, Inc. (NASDAQ:HJLI) ("Hancock Jaffe" or the "Company"), a medical device company focused on improving the standard of care in the treatment of venous disease, today announced that Robert Berman, CEO of Hancock Jaffe will participate in The Duologue Series hosted by Ladenburg Thalmann |
Hancock Jaffe Announces Corporate Rebranding to Reflect Prioritization of its Development Pipeline on Venous Disease Programs\- Hancock Jaffe changing name to enVVeno Medical Corporation and ticker symbol to NASDAQ: NVNO, effective October 1, 2021 -\- Development strategy to focus on venous disease and advancement of the VenoValve® -\- Initiated development of second product for the treatment of venous disease; expected to be unveiled in mid-2022 -\- Management to host a conference call with live video webcast at 4:30 p. ET today, September 21st -IRVINE, CA / ACCESSWIRE / September 21, 2021 / Hancock Jaffe Laboratorie |
Multiple insiders bought Hancock Jaffe Laboratories, Inc. (NASDAQ:HJLI) stock earlier this year, a positive sign for shareholdersGenerally, when a single insider buys stock, it is usually not a big deal. However, when several insiders are buying... |
Hancock Jaffe to Host Corporate Update Conference Call and Webcast on September 21, 2021Conference call with live video webcast to be held on Tuesday, September 21st at 4:30 p. ETIRVINE, CA / ACCESSWIRE / September 15, 2021 / Hancock Jaffe Laboratories, Inc. |
HJLI Price Returns
| 1-mo | N/A |
| 3-mo | N/A |
| 6-mo | N/A |
| 1-year | N/A |
| 3-year | 27.36% |
| 5-year | -92.08% |
| YTD | N/A |
| 2022 | N/A |
| 2021 | 0.00% |
| 2020 | -37.09% |
| 2019 | -62.71% |
| 2018 | N/A |
Continue Researching HJLI
Here are a few links from around the web to help you further your research on Hancock Jaffe Laboratories Inc's stock as an investment opportunity:Hancock Jaffe Laboratories Inc (HJLI) Stock Price | Nasdaq
Hancock Jaffe Laboratories Inc (HJLI) Stock Quote, History and News - Yahoo Finance
Hancock Jaffe Laboratories Inc (HJLI) Stock Price and Basic Information | MarketWatch
Loading social stream, please wait...